Kopran Stock Falls to 52-Week Low of Rs.137 Amidst Continued Downtrend

Nov 18 2025 09:56 AM IST
share
Share Via
Kopran, a company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low price of Rs.137 today, marking a significant decline amid a sustained downward trend. The stock has been trading below all key moving averages and has recorded losses over the past six consecutive sessions, reflecting ongoing challenges in its financial performance.



The stock’s fall to Rs.137 represents a notable drop from its 52-week high of Rs.236.1, underscoring a substantial depreciation in value over the past year. Kopran’s performance over the last 12 months shows a return of -38.07%, contrasting sharply with the Sensex’s positive return of 9.48% during the same period. This divergence highlights the stock’s relative underperformance within the broader market context.



Today, Kopran’s share price declined by 1.04%, underperforming its sector by 0.74%. The stock is currently trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent bearish trend. Over the last six trading days, the stock has lost approximately 14.36% in value, signalling sustained selling pressure.




Why settle for Kopran ? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!



  • Comprehensive evaluation done

  • Superior opportunities identified

  • Smart switching enabled


Discover Superior Stocks →




Examining Kopran’s financial metrics reveals several factors contributing to its current valuation. The company has reported negative results for five consecutive quarters, including the most recent quarter ending September 2025. Net sales declined by 22.2% in this period, while the quarterly profit after tax (PAT) stood at a loss of Rs.9.92 crore, reflecting a fall of 234.4% compared to previous periods.



Operating profit has shown a negative compound annual growth rate of 11.79% over the last five years, indicating challenges in sustaining profitability. The company’s return on capital employed (ROCE) for the half-year ended recently is recorded at 5.38%, one of the lowest levels observed. Additionally, the operating profit to interest coverage ratio for the quarter is at -2.53 times, signalling difficulties in covering interest expenses from operating earnings.



Despite these financial headwinds, Kopran maintains a relatively low average debt-to-equity ratio of 0.23 times, which suggests limited leverage on its balance sheet. The enterprise value to capital employed ratio stands at 1.3, indicating that the stock is trading at a valuation discount relative to its capital base and compared to peers’ historical averages.



Over the past year, Kopran’s profits have contracted by 66.7%, further reflecting the pressures on its earnings capacity. The stock’s underperformance extends beyond the last year, with returns lagging behind the BSE500 index over the last three years, one year, and three months, highlighting a longer-term trend of subdued market performance.




Considering Kopran ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!



  • Better options discovered

  • Pharmaceuticals & Biotechnology + beyond scope

  • Top-rated alternatives ready


Compare & Switch Now →




In the broader market context, the Sensex opened positively with a gain of 91.42 points but subsequently declined by 381.14 points, trading at 84,661.23 at the time of reporting, down 0.34%. The index remains close to its 52-week high of 85,290.06, just 0.74% away, and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a generally bullish trend for the benchmark index.



Within this environment, Kopran’s stock has not mirrored the broader market’s resilience. Domestic mutual funds hold a minimal stake of 0.01% in the company, which may reflect a cautious stance given the company’s recent financial disclosures and market performance. This limited institutional holding contrasts with the company’s market capitalisation grade of 4, suggesting a mid-sized presence in the market but with subdued fund interest.



Overall, Kopran’s stock has experienced a significant decline to its 52-week low of Rs.137, driven by a combination of declining sales, consecutive negative quarterly results, and subdued profitability metrics. The stock’s trading below all major moving averages and its underperformance relative to sector and market indices underscore the challenges faced by the company in recent periods.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News